Technology | May 16, 2013

Positron Introduces Next Generation PosiRx Pharmacy Automation Systems

Positron Corp PosiRx 3000-Series Pharmacy Automation Systems

May 16, 2013 — Positron Corp. announced the release of the PosiRx 3000-Series, its latest pharmacy automation systems. The PosiRx 3000-Series are the first systems to automate and encompass the complete compounding process, from generator elution to dose distribution, of multiple diagnostic single photon emission computed tomography (SPECT) agents in an environment engineered to be ISO Class 5 and USP 797 compliant. Designed for facilities dispensing as many as 300 patient-specific doses per day, the PosiRx 3000-Series will benefit providers and patients by enabling unit dose radiopharmaceuticals to be prepared more cost effectively and accurately than previously possible.

The PosiRx line of automation systems features DoseLink, Positron's state of the art proprietary software. Developed for precision and customer ease of use, DoseLink maximizes the functionality and efficiency of operating the PosiRx system through a robust and intuitive interface that can be operated from a variety of interfaces. Whether accessed from a desktop, tablet or smartphone, DoseLink empowers the user to control drug preparation and plan daily production, as well as store and retrieve data in a secure environment. Additionally, the operator may interact with Positron support personnel for assistance with any task in real time, across any platform.

"The release of the PosiRx 3000-Series is a true milestone that marks the next phase in nuclear pharmacy automation," stated Charles Conroy, RPh, MBA, Positron's chief operating officer. "For over 20 years, the nuclear pharmacy community has been seeking an automation solution that can efficiently and accurately prepare patient specific unit doses. Through the ability to compound a wide selection of radiopharmaceuticals, coupled with the system's speed and efficiency, the 3000-Series is that solution and stands in a class by itself. By powering the system with DoseLink, PosiRx users will benefit from the unprecedented flexibility and control to operate across all types of devices and a variety of platforms. By controlling the preparation process from any place at any time, our customers will see significant revenue enhancement from increased patient throughput and a decrease in cost of goods."

To support commercialization efforts, Positron has launched a dedicated website for the PosiRx portfolio of products. The new website is part of Positron's plan to further develop its corporate identity and is designed to help distinguish between the company's cardiac positron emission tomography (PET) business and high tech automation products. By highlighting innovative features and further expanding its capabilities, the site allows visitors to gain a comprehensive understanding of the PosiRx System.

Conroy added, "The PosiRx system with DoseLink software provides a solid platform for growth into other diagnostic areas, additional pharmaceutical classes and new markets. The dedicated website will be very important as we work with our partners to expand Positron's offerings."

For more information: www.positron.com

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init